BioSpace News Archive

Quince Therapeutics, Inc. today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Bruker Corporation has been selected as the Instrument Business Outlook ‘Company of the Year’ for 2023.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).

Antibe Therapeutics Inc. announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial.

Baxter International Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – enables clinicians to utilize a single, integrated system across a variety of patient care settings.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

3M completed the planned spin-off of its health care business, which formally launches Solventum Corporation as an independent company.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, provides a business update and announces financial results for the year ending December 31, 2023.

Turbine and Harmonic Discovery have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023.